The FDA recently announced its approval of Gilead Sciences’ hepatitis C combination drug Harvoni to be used with Sovaldi is the first oral combination therapy approved for Hep C, as well as the first regimen that does not need to be administered with interferon or ribavirin. Harvoni will be priced at $94,500 for a standard 12-week course. Read more here. (Source: FirstWord Pharma, 10/10/14).
You are here: / / Meet Sovaldi’s New Sidekick – Harvoni